nodes	percent_of_prediction	percent_of_DWPC	metapath
Dipyridamole—ABCC4—Sorafenib—liver cancer	0.187	0.762	CbGbCtD
Dipyridamole—ABCB1—Sorafenib—liver cancer	0.0362	0.148	CbGbCtD
Dipyridamole—ABCB1—Doxorubicin—liver cancer	0.022	0.0897	CbGbCtD
Dipyridamole—Anorectal discomfort—Doxorubicin—liver cancer	0.00251	0.00877	CcSEcCtD
Dipyridamole—Abdominal discomfort—Sorafenib—liver cancer	0.00242	0.00843	CcSEcCtD
Dipyridamole—Acute coronary syndrome—Sorafenib—liver cancer	0.00222	0.00773	CcSEcCtD
Dipyridamole—Myocardial infarction—Sorafenib—liver cancer	0.0022	0.00769	CcSEcCtD
Dipyridamole—Hyperventilation—Epirubicin—liver cancer	0.00216	0.00753	CcSEcCtD
Dipyridamole—Haemoglobin—Sorafenib—liver cancer	0.00203	0.00708	CcSEcCtD
Dipyridamole—Haemorrhage—Sorafenib—liver cancer	0.00202	0.00704	CcSEcCtD
Dipyridamole—Ventricular arrhythmia—Epirubicin—liver cancer	0.00201	0.007	CcSEcCtD
Dipyridamole—Hyperventilation—Doxorubicin—liver cancer	0.002	0.00697	CcSEcCtD
Dipyridamole—Tinnitus—Sorafenib—liver cancer	0.00188	0.00657	CcSEcCtD
Dipyridamole—Cardiac disorder—Sorafenib—liver cancer	0.00187	0.00654	CcSEcCtD
Dipyridamole—Flushing—Sorafenib—liver cancer	0.00187	0.00654	CcSEcCtD
Dipyridamole—Ventricular arrhythmia—Doxorubicin—liver cancer	0.00186	0.00648	CcSEcCtD
Dipyridamole—Angiopathy—Sorafenib—liver cancer	0.00183	0.00639	CcSEcCtD
Dipyridamole—Immune system disorder—Sorafenib—liver cancer	0.00182	0.00636	CcSEcCtD
Dipyridamole—Injection site pain—Epirubicin—liver cancer	0.00182	0.00635	CcSEcCtD
Dipyridamole—Rigors—Epirubicin—liver cancer	0.00182	0.00635	CcSEcCtD
Dipyridamole—Mediastinal disorder—Sorafenib—liver cancer	0.00182	0.00635	CcSEcCtD
Dipyridamole—Dysphonia—Epirubicin—liver cancer	0.0018	0.0063	CcSEcCtD
Dipyridamole—Arrhythmia—Sorafenib—liver cancer	0.0018	0.00629	CcSEcCtD
Dipyridamole—Alopecia—Sorafenib—liver cancer	0.00178	0.00622	CcSEcCtD
Dipyridamole—Dysgeusia—Sorafenib—liver cancer	0.00172	0.006	CcSEcCtD
Dipyridamole—Breast pain—Epirubicin—liver cancer	0.0017	0.00594	CcSEcCtD
Dipyridamole—Muscle spasms—Sorafenib—liver cancer	0.00169	0.00589	CcSEcCtD
Dipyridamole—Rigors—Doxorubicin—liver cancer	0.00168	0.00587	CcSEcCtD
Dipyridamole—Injection site pain—Doxorubicin—liver cancer	0.00168	0.00587	CcSEcCtD
Dipyridamole—Dysphonia—Doxorubicin—liver cancer	0.00167	0.00583	CcSEcCtD
Dipyridamole—Bone disorder—Epirubicin—liver cancer	0.00164	0.00574	CcSEcCtD
Dipyridamole—Ventricular extrasystoles—Epirubicin—liver cancer	0.00164	0.00574	CcSEcCtD
Dipyridamole—Anaemia—Sorafenib—liver cancer	0.00162	0.00567	CcSEcCtD
Dipyridamole—Angioedema—Sorafenib—liver cancer	0.0016	0.0056	CcSEcCtD
Dipyridamole—Syncope—Sorafenib—liver cancer	0.00157	0.0055	CcSEcCtD
Dipyridamole—Breast pain—Doxorubicin—liver cancer	0.00157	0.0055	CcSEcCtD
Dipyridamole—Loss of consciousness—Sorafenib—liver cancer	0.00154	0.00539	CcSEcCtD
Dipyridamole—Cough—Sorafenib—liver cancer	0.00153	0.00535	CcSEcCtD
Dipyridamole—Atrioventricular block—Epirubicin—liver cancer	0.00153	0.00534	CcSEcCtD
Dipyridamole—Bone disorder—Doxorubicin—liver cancer	0.00152	0.00531	CcSEcCtD
Dipyridamole—Ventricular extrasystoles—Doxorubicin—liver cancer	0.00152	0.00531	CcSEcCtD
Dipyridamole—Hypertension—Sorafenib—liver cancer	0.00152	0.00529	CcSEcCtD
Dipyridamole—Coordination abnormal—Epirubicin—liver cancer	0.00151	0.00528	CcSEcCtD
Dipyridamole—Musculoskeletal pain—Epirubicin—liver cancer	0.0015	0.00525	CcSEcCtD
Dipyridamole—Myalgia—Sorafenib—liver cancer	0.0015	0.00522	CcSEcCtD
Dipyridamole—Arthralgia—Sorafenib—liver cancer	0.0015	0.00522	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00148	0.00518	CcSEcCtD
Dipyridamole—Ventricular tachycardia—Epirubicin—liver cancer	0.00148	0.00518	CcSEcCtD
Dipyridamole—Injection site reaction—Epirubicin—liver cancer	0.00148	0.00515	CcSEcCtD
Dipyridamole—Dry mouth—Sorafenib—liver cancer	0.00146	0.0051	CcSEcCtD
Dipyridamole—Eructation—Epirubicin—liver cancer	0.00146	0.00509	CcSEcCtD
Dipyridamole—Anaphylactic shock—Sorafenib—liver cancer	0.00143	0.005	CcSEcCtD
Dipyridamole—Atrioventricular block—Doxorubicin—liver cancer	0.00142	0.00494	CcSEcCtD
Dipyridamole—Shock—Sorafenib—liver cancer	0.00141	0.00492	CcSEcCtD
Dipyridamole—Nervous system disorder—Sorafenib—liver cancer	0.00141	0.00491	CcSEcCtD
Dipyridamole—Thrombocytopenia—Sorafenib—liver cancer	0.0014	0.0049	CcSEcCtD
Dipyridamole—Coordination abnormal—Doxorubicin—liver cancer	0.0014	0.00488	CcSEcCtD
Dipyridamole—Skin disorder—Sorafenib—liver cancer	0.00139	0.00486	CcSEcCtD
Dipyridamole—Musculoskeletal pain—Doxorubicin—liver cancer	0.00139	0.00485	CcSEcCtD
Dipyridamole—Ventricular tachycardia—Doxorubicin—liver cancer	0.00137	0.0048	CcSEcCtD
Dipyridamole—Injection site reaction—Doxorubicin—liver cancer	0.00137	0.00477	CcSEcCtD
Dipyridamole—Eructation—Doxorubicin—liver cancer	0.00135	0.00471	CcSEcCtD
Dipyridamole—Pulmonary oedema—Epirubicin—liver cancer	0.00132	0.00461	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00131	0.00456	CcSEcCtD
Dipyridamole—Hypertonia—Epirubicin—liver cancer	0.0013	0.00454	CcSEcCtD
Dipyridamole—Dyspnoea—Sorafenib—liver cancer	0.00128	0.00446	CcSEcCtD
Dipyridamole—Dyspepsia—Sorafenib—liver cancer	0.00126	0.0044	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Sorafenib—liver cancer	0.00124	0.00432	CcSEcCtD
Dipyridamole—Fatigue—Sorafenib—liver cancer	0.00124	0.00431	CcSEcCtD
Dipyridamole—Hepatic function abnormal—Epirubicin—liver cancer	0.00123	0.0043	CcSEcCtD
Dipyridamole—Pain—Sorafenib—liver cancer	0.00123	0.00428	CcSEcCtD
Dipyridamole—Pulmonary oedema—Doxorubicin—liver cancer	0.00122	0.00427	CcSEcCtD
Dipyridamole—Hypertonia—Doxorubicin—liver cancer	0.0012	0.0042	CcSEcCtD
Dipyridamole—Eye pain—Epirubicin—liver cancer	0.00119	0.00417	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Sorafenib—liver cancer	0.00117	0.00409	CcSEcCtD
Dipyridamole—Hot flush—Epirubicin—liver cancer	0.00115	0.00402	CcSEcCtD
Dipyridamole—Increased appetite—Epirubicin—liver cancer	0.00115	0.004	CcSEcCtD
Dipyridamole—Menopausal symptoms—Epirubicin—liver cancer	0.00114	0.00399	CcSEcCtD
Dipyridamole—Hepatic function abnormal—Doxorubicin—liver cancer	0.00114	0.00398	CcSEcCtD
Dipyridamole—Urticaria—Sorafenib—liver cancer	0.00114	0.00397	CcSEcCtD
Dipyridamole—Abdominal pain—Sorafenib—liver cancer	0.00113	0.00396	CcSEcCtD
Dipyridamole—Anaphylactoid reaction—Epirubicin—liver cancer	0.00111	0.00389	CcSEcCtD
Dipyridamole—Eye pain—Doxorubicin—liver cancer	0.0011	0.00386	CcSEcCtD
Dipyridamole—Cerebrovascular accident—Epirubicin—liver cancer	0.0011	0.00384	CcSEcCtD
Dipyridamole—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.00108	0.00376	CcSEcCtD
Dipyridamole—Hot flush—Doxorubicin—liver cancer	0.00107	0.00372	CcSEcCtD
Dipyridamole—Increased appetite—Doxorubicin—liver cancer	0.00106	0.00371	CcSEcCtD
Dipyridamole—Migraine—Epirubicin—liver cancer	0.00106	0.0037	CcSEcCtD
Dipyridamole—Menopausal symptoms—Doxorubicin—liver cancer	0.00106	0.00369	CcSEcCtD
Dipyridamole—Hypersensitivity—Sorafenib—liver cancer	0.00106	0.00369	CcSEcCtD
Dipyridamole—Anaphylactoid reaction—Doxorubicin—liver cancer	0.00103	0.0036	CcSEcCtD
Dipyridamole—Asthenia—Sorafenib—liver cancer	0.00103	0.00359	CcSEcCtD
Dipyridamole—Cardiac arrest—Epirubicin—liver cancer	0.00102	0.00358	CcSEcCtD
Dipyridamole—Cerebrovascular accident—Doxorubicin—liver cancer	0.00102	0.00355	CcSEcCtD
Dipyridamole—Pruritus—Sorafenib—liver cancer	0.00101	0.00354	CcSEcCtD
Dipyridamole—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.000997	0.00348	CcSEcCtD
Dipyridamole—Orthostatic hypotension—Epirubicin—liver cancer	0.000984	0.00344	CcSEcCtD
Dipyridamole—Abdominal pain upper—Epirubicin—liver cancer	0.000984	0.00344	CcSEcCtD
Dipyridamole—Migraine—Doxorubicin—liver cancer	0.000981	0.00343	CcSEcCtD
Dipyridamole—Diarrhoea—Sorafenib—liver cancer	0.000981	0.00342	CcSEcCtD
Dipyridamole—Cardiac arrest—Doxorubicin—liver cancer	0.000948	0.00331	CcSEcCtD
Dipyridamole—Dizziness—Sorafenib—liver cancer	0.000948	0.00331	CcSEcCtD
Dipyridamole—Dysphagia—Epirubicin—liver cancer	0.000931	0.00325	CcSEcCtD
Dipyridamole—Vomiting—Sorafenib—liver cancer	0.000911	0.00318	CcSEcCtD
Dipyridamole—Orthostatic hypotension—Doxorubicin—liver cancer	0.000911	0.00318	CcSEcCtD
Dipyridamole—Abdominal pain upper—Doxorubicin—liver cancer	0.000911	0.00318	CcSEcCtD
Dipyridamole—Angina pectoris—Epirubicin—liver cancer	0.000907	0.00317	CcSEcCtD
Dipyridamole—Rash—Sorafenib—liver cancer	0.000904	0.00315	CcSEcCtD
Dipyridamole—Dermatitis—Sorafenib—liver cancer	0.000903	0.00315	CcSEcCtD
Dipyridamole—Headache—Sorafenib—liver cancer	0.000898	0.00313	CcSEcCtD
Dipyridamole—Dysphagia—Doxorubicin—liver cancer	0.000862	0.00301	CcSEcCtD
Dipyridamole—Nausea—Sorafenib—liver cancer	0.000851	0.00297	CcSEcCtD
Dipyridamole—Angina pectoris—Doxorubicin—liver cancer	0.00084	0.00293	CcSEcCtD
Dipyridamole—Bradycardia—Epirubicin—liver cancer	0.000759	0.00265	CcSEcCtD
Dipyridamole—Haemoglobin—Epirubicin—liver cancer	0.000749	0.00262	CcSEcCtD
Dipyridamole—Rhinitis—Epirubicin—liver cancer	0.000747	0.00261	CcSEcCtD
Dipyridamole—Haemorrhage—Epirubicin—liver cancer	0.000746	0.0026	CcSEcCtD
Dipyridamole—Hepatitis—Epirubicin—liver cancer	0.000746	0.0026	CcSEcCtD
Dipyridamole—Hypoaesthesia—Epirubicin—liver cancer	0.000742	0.00259	CcSEcCtD
Dipyridamole—Pharyngitis—Epirubicin—liver cancer	0.00074	0.00258	CcSEcCtD
Dipyridamole—Bradycardia—Doxorubicin—liver cancer	0.000702	0.00245	CcSEcCtD
Dipyridamole—Tinnitus—Epirubicin—liver cancer	0.000695	0.00243	CcSEcCtD
Dipyridamole—Haemoglobin—Doxorubicin—liver cancer	0.000693	0.00242	CcSEcCtD
Dipyridamole—Flushing—Epirubicin—liver cancer	0.000692	0.00242	CcSEcCtD
Dipyridamole—Cardiac disorder—Epirubicin—liver cancer	0.000692	0.00242	CcSEcCtD
Dipyridamole—Rhinitis—Doxorubicin—liver cancer	0.000692	0.00241	CcSEcCtD
Dipyridamole—Hepatitis—Doxorubicin—liver cancer	0.00069	0.00241	CcSEcCtD
Dipyridamole—Haemorrhage—Doxorubicin—liver cancer	0.00069	0.00241	CcSEcCtD
Dipyridamole—Hypoaesthesia—Doxorubicin—liver cancer	0.000686	0.0024	CcSEcCtD
Dipyridamole—Pharyngitis—Doxorubicin—liver cancer	0.000685	0.00239	CcSEcCtD
Dipyridamole—Angiopathy—Epirubicin—liver cancer	0.000676	0.00236	CcSEcCtD
Dipyridamole—Immune system disorder—Epirubicin—liver cancer	0.000673	0.00235	CcSEcCtD
Dipyridamole—Mediastinal disorder—Epirubicin—liver cancer	0.000672	0.00235	CcSEcCtD
Dipyridamole—Chills—Epirubicin—liver cancer	0.000669	0.00234	CcSEcCtD
Dipyridamole—Arrhythmia—Epirubicin—liver cancer	0.000666	0.00233	CcSEcCtD
Dipyridamole—Alopecia—Epirubicin—liver cancer	0.000659	0.0023	CcSEcCtD
Dipyridamole—Tinnitus—Doxorubicin—liver cancer	0.000643	0.00225	CcSEcCtD
Dipyridamole—Cardiac disorder—Doxorubicin—liver cancer	0.00064	0.00223	CcSEcCtD
Dipyridamole—Flushing—Doxorubicin—liver cancer	0.00064	0.00223	CcSEcCtD
Dipyridamole—Flatulence—Epirubicin—liver cancer	0.00064	0.00223	CcSEcCtD
Dipyridamole—Tension—Epirubicin—liver cancer	0.000637	0.00222	CcSEcCtD
Dipyridamole—Dysgeusia—Epirubicin—liver cancer	0.000636	0.00222	CcSEcCtD
Dipyridamole—Nervousness—Epirubicin—liver cancer	0.00063	0.0022	CcSEcCtD
Dipyridamole—Back pain—Epirubicin—liver cancer	0.000628	0.00219	CcSEcCtD
Dipyridamole—Angiopathy—Doxorubicin—liver cancer	0.000626	0.00218	CcSEcCtD
Dipyridamole—Muscle spasms—Epirubicin—liver cancer	0.000624	0.00218	CcSEcCtD
Dipyridamole—Immune system disorder—Doxorubicin—liver cancer	0.000623	0.00218	CcSEcCtD
Dipyridamole—Mediastinal disorder—Doxorubicin—liver cancer	0.000622	0.00217	CcSEcCtD
Dipyridamole—Chills—Doxorubicin—liver cancer	0.000619	0.00216	CcSEcCtD
Dipyridamole—Arrhythmia—Doxorubicin—liver cancer	0.000616	0.00215	CcSEcCtD
Dipyridamole—Alopecia—Doxorubicin—liver cancer	0.00061	0.00213	CcSEcCtD
Dipyridamole—Ill-defined disorder—Epirubicin—liver cancer	0.000602	0.0021	CcSEcCtD
Dipyridamole—Anaemia—Epirubicin—liver cancer	0.0006	0.00209	CcSEcCtD
Dipyridamole—Flatulence—Doxorubicin—liver cancer	0.000592	0.00207	CcSEcCtD
Dipyridamole—Tension—Doxorubicin—liver cancer	0.000589	0.00206	CcSEcCtD
Dipyridamole—Dysgeusia—Doxorubicin—liver cancer	0.000588	0.00205	CcSEcCtD
Dipyridamole—Malaise—Epirubicin—liver cancer	0.000585	0.00204	CcSEcCtD
Dipyridamole—Nervousness—Doxorubicin—liver cancer	0.000583	0.00204	CcSEcCtD
Dipyridamole—Vertigo—Epirubicin—liver cancer	0.000583	0.00204	CcSEcCtD
Dipyridamole—Syncope—Epirubicin—liver cancer	0.000582	0.00203	CcSEcCtD
Dipyridamole—Back pain—Doxorubicin—liver cancer	0.000581	0.00203	CcSEcCtD
Dipyridamole—Muscle spasms—Doxorubicin—liver cancer	0.000577	0.00202	CcSEcCtD
Dipyridamole—Palpitations—Epirubicin—liver cancer	0.000574	0.002	CcSEcCtD
Dipyridamole—Loss of consciousness—Epirubicin—liver cancer	0.00057	0.00199	CcSEcCtD
Dipyridamole—Cough—Epirubicin—liver cancer	0.000566	0.00198	CcSEcCtD
Dipyridamole—Convulsion—Epirubicin—liver cancer	0.000562	0.00196	CcSEcCtD
Dipyridamole—Hypertension—Epirubicin—liver cancer	0.00056	0.00196	CcSEcCtD
Dipyridamole—Ill-defined disorder—Doxorubicin—liver cancer	0.000557	0.00195	CcSEcCtD
Dipyridamole—Anaemia—Doxorubicin—liver cancer	0.000555	0.00194	CcSEcCtD
Dipyridamole—Myalgia—Epirubicin—liver cancer	0.000553	0.00193	CcSEcCtD
Dipyridamole—Chest pain—Epirubicin—liver cancer	0.000553	0.00193	CcSEcCtD
Dipyridamole—Arthralgia—Epirubicin—liver cancer	0.000553	0.00193	CcSEcCtD
Dipyridamole—Anxiety—Epirubicin—liver cancer	0.000551	0.00192	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000549	0.00192	CcSEcCtD
Dipyridamole—Discomfort—Epirubicin—liver cancer	0.000546	0.00191	CcSEcCtD
Dipyridamole—Malaise—Doxorubicin—liver cancer	0.000542	0.00189	CcSEcCtD
Dipyridamole—Dry mouth—Epirubicin—liver cancer	0.00054	0.00189	CcSEcCtD
Dipyridamole—Vertigo—Doxorubicin—liver cancer	0.00054	0.00188	CcSEcCtD
Dipyridamole—Syncope—Doxorubicin—liver cancer	0.000539	0.00188	CcSEcCtD
Dipyridamole—Palpitations—Doxorubicin—liver cancer	0.000531	0.00185	CcSEcCtD
Dipyridamole—Anaphylactic shock—Epirubicin—liver cancer	0.00053	0.00185	CcSEcCtD
Dipyridamole—Oedema—Epirubicin—liver cancer	0.00053	0.00185	CcSEcCtD
Dipyridamole—Loss of consciousness—Doxorubicin—liver cancer	0.000528	0.00184	CcSEcCtD
Dipyridamole—Cough—Doxorubicin—liver cancer	0.000524	0.00183	CcSEcCtD
Dipyridamole—Shock—Epirubicin—liver cancer	0.000521	0.00182	CcSEcCtD
Dipyridamole—Convulsion—Doxorubicin—liver cancer	0.00052	0.00182	CcSEcCtD
Dipyridamole—Nervous system disorder—Epirubicin—liver cancer	0.000519	0.00181	CcSEcCtD
Dipyridamole—Thrombocytopenia—Epirubicin—liver cancer	0.000519	0.00181	CcSEcCtD
Dipyridamole—Hypertension—Doxorubicin—liver cancer	0.000518	0.00181	CcSEcCtD
Dipyridamole—Tachycardia—Epirubicin—liver cancer	0.000517	0.0018	CcSEcCtD
Dipyridamole—Skin disorder—Epirubicin—liver cancer	0.000514	0.0018	CcSEcCtD
Dipyridamole—Hyperhidrosis—Epirubicin—liver cancer	0.000512	0.00179	CcSEcCtD
Dipyridamole—Arthralgia—Doxorubicin—liver cancer	0.000511	0.00178	CcSEcCtD
Dipyridamole—Chest pain—Doxorubicin—liver cancer	0.000511	0.00178	CcSEcCtD
Dipyridamole—Myalgia—Doxorubicin—liver cancer	0.000511	0.00178	CcSEcCtD
Dipyridamole—Anxiety—Doxorubicin—liver cancer	0.000509	0.00178	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000508	0.00177	CcSEcCtD
Dipyridamole—Discomfort—Doxorubicin—liver cancer	0.000505	0.00176	CcSEcCtD
Dipyridamole—Dry mouth—Doxorubicin—liver cancer	0.0005	0.00175	CcSEcCtD
Dipyridamole—Hypotension—Epirubicin—liver cancer	0.000495	0.00173	CcSEcCtD
Dipyridamole—Oedema—Doxorubicin—liver cancer	0.00049	0.00171	CcSEcCtD
Dipyridamole—Anaphylactic shock—Doxorubicin—liver cancer	0.00049	0.00171	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000483	0.00168	CcSEcCtD
Dipyridamole—Shock—Doxorubicin—liver cancer	0.000482	0.00168	CcSEcCtD
Dipyridamole—Nervous system disorder—Doxorubicin—liver cancer	0.000481	0.00168	CcSEcCtD
Dipyridamole—Thrombocytopenia—Doxorubicin—liver cancer	0.00048	0.00168	CcSEcCtD
Dipyridamole—Tachycardia—Doxorubicin—liver cancer	0.000478	0.00167	CcSEcCtD
Dipyridamole—Skin disorder—Doxorubicin—liver cancer	0.000476	0.00166	CcSEcCtD
Dipyridamole—Paraesthesia—Epirubicin—liver cancer	0.000476	0.00166	CcSEcCtD
Dipyridamole—Hyperhidrosis—Doxorubicin—liver cancer	0.000474	0.00165	CcSEcCtD
Dipyridamole—Dyspnoea—Epirubicin—liver cancer	0.000472	0.00165	CcSEcCtD
Dipyridamole—Somnolence—Epirubicin—liver cancer	0.000471	0.00164	CcSEcCtD
Dipyridamole—Dyspepsia—Epirubicin—liver cancer	0.000466	0.00163	CcSEcCtD
Dipyridamole—Hypotension—Doxorubicin—liver cancer	0.000458	0.0016	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Epirubicin—liver cancer	0.000457	0.0016	CcSEcCtD
Dipyridamole—Fatigue—Epirubicin—liver cancer	0.000457	0.00159	CcSEcCtD
Dipyridamole—Pain—Epirubicin—liver cancer	0.000453	0.00158	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000447	0.00156	CcSEcCtD
Dipyridamole—Paraesthesia—Doxorubicin—liver cancer	0.00044	0.00154	CcSEcCtD
Dipyridamole—Dyspnoea—Doxorubicin—liver cancer	0.000437	0.00153	CcSEcCtD
Dipyridamole—Feeling abnormal—Epirubicin—liver cancer	0.000436	0.00152	CcSEcCtD
Dipyridamole—Somnolence—Doxorubicin—liver cancer	0.000436	0.00152	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Epirubicin—liver cancer	0.000433	0.00151	CcSEcCtD
Dipyridamole—Dyspepsia—Doxorubicin—liver cancer	0.000431	0.00151	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000423	0.00148	CcSEcCtD
Dipyridamole—Fatigue—Doxorubicin—liver cancer	0.000423	0.00148	CcSEcCtD
Dipyridamole—Urticaria—Epirubicin—liver cancer	0.000421	0.00147	CcSEcCtD
Dipyridamole—Pain—Doxorubicin—liver cancer	0.000419	0.00146	CcSEcCtD
Dipyridamole—Abdominal pain—Epirubicin—liver cancer	0.000419	0.00146	CcSEcCtD
Dipyridamole—Feeling abnormal—Doxorubicin—liver cancer	0.000404	0.00141	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Doxorubicin—liver cancer	0.000401	0.0014	CcSEcCtD
Dipyridamole—Hypersensitivity—Epirubicin—liver cancer	0.00039	0.00136	CcSEcCtD
Dipyridamole—Urticaria—Doxorubicin—liver cancer	0.000389	0.00136	CcSEcCtD
Dipyridamole—Abdominal pain—Doxorubicin—liver cancer	0.000387	0.00135	CcSEcCtD
Dipyridamole—Asthenia—Epirubicin—liver cancer	0.00038	0.00133	CcSEcCtD
Dipyridamole—Pruritus—Epirubicin—liver cancer	0.000375	0.00131	CcSEcCtD
Dipyridamole—Diarrhoea—Epirubicin—liver cancer	0.000362	0.00127	CcSEcCtD
Dipyridamole—Hypersensitivity—Doxorubicin—liver cancer	0.000361	0.00126	CcSEcCtD
Dipyridamole—Asthenia—Doxorubicin—liver cancer	0.000352	0.00123	CcSEcCtD
Dipyridamole—Dizziness—Epirubicin—liver cancer	0.00035	0.00122	CcSEcCtD
Dipyridamole—Pruritus—Doxorubicin—liver cancer	0.000347	0.00121	CcSEcCtD
Dipyridamole—Vomiting—Epirubicin—liver cancer	0.000337	0.00118	CcSEcCtD
Dipyridamole—Diarrhoea—Doxorubicin—liver cancer	0.000335	0.00117	CcSEcCtD
Dipyridamole—Rash—Epirubicin—liver cancer	0.000334	0.00117	CcSEcCtD
Dipyridamole—Dermatitis—Epirubicin—liver cancer	0.000334	0.00116	CcSEcCtD
Dipyridamole—Headache—Epirubicin—liver cancer	0.000332	0.00116	CcSEcCtD
Dipyridamole—Dizziness—Doxorubicin—liver cancer	0.000324	0.00113	CcSEcCtD
Dipyridamole—Nausea—Epirubicin—liver cancer	0.000315	0.0011	CcSEcCtD
Dipyridamole—Vomiting—Doxorubicin—liver cancer	0.000312	0.00109	CcSEcCtD
Dipyridamole—Rash—Doxorubicin—liver cancer	0.000309	0.00108	CcSEcCtD
Dipyridamole—Dermatitis—Doxorubicin—liver cancer	0.000309	0.00108	CcSEcCtD
Dipyridamole—Headache—Doxorubicin—liver cancer	0.000307	0.00107	CcSEcCtD
Dipyridamole—Nausea—Doxorubicin—liver cancer	0.000291	0.00102	CcSEcCtD
Dipyridamole—ABCC5—Metabolism—PIK3CB—liver cancer	3.17e-05	6.77e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—MAPK8—liver cancer	3.17e-05	6.76e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—STAT3—liver cancer	3.17e-05	6.76e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—KRAS—liver cancer	3.17e-05	6.76e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—TP53—liver cancer	3.16e-05	6.75e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—TP53—liver cancer	3.16e-05	6.75e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—APC—liver cancer	3.16e-05	6.75e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PIK3CG—liver cancer	3.16e-05	6.75e-05	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—AKT1—liver cancer	3.14e-05	6.71e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GSTA1—liver cancer	3.13e-05	6.69e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	3.13e-05	6.69e-05	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—IL6—liver cancer	3.12e-05	6.65e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	3.11e-05	6.63e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—NAT2—liver cancer	3.1e-05	6.62e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—MTOR—liver cancer	3.09e-05	6.61e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—PIK3CB—liver cancer	3.09e-05	6.61e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—CTNNB1—liver cancer	3.07e-05	6.55e-05	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—HRAS—liver cancer	3.06e-05	6.52e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PIK3CD—liver cancer	3.04e-05	6.49e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—PIK3CA—liver cancer	3.03e-05	6.47e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—HRAS—liver cancer	3.03e-05	6.46e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—HRAS—liver cancer	3.03e-05	6.46e-05	CbGpPWpGaD
Dipyridamole—PDE1A—GPCR downstream signaling—PIK3CA—liver cancer	3.01e-05	6.43e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—SERPINE1—liver cancer	3.01e-05	6.42e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—CDKN1A—liver cancer	3e-05	6.4e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—PIK3CA—liver cancer	2.99e-05	6.39e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—PIK3CA—liver cancer	2.99e-05	6.38e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—KRAS—liver cancer	2.98e-05	6.35e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—BRAF—liver cancer	2.97e-05	6.35e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—ALDOB—liver cancer	2.97e-05	6.34e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—RAF1—liver cancer	2.97e-05	6.34e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—HRAS—liver cancer	2.95e-05	6.31e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—TP53—liver cancer	2.93e-05	6.26e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—STAT3—liver cancer	2.92e-05	6.24e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—STAT3—liver cancer	2.92e-05	6.24e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—PIK3CA—liver cancer	2.91e-05	6.22e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—PIK3CA—liver cancer	2.91e-05	6.21e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CDKN1B—liver cancer	2.9e-05	6.2e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—MTOR—liver cancer	2.9e-05	6.19e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—PIK3CB—liver cancer	2.9e-05	6.19e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—STAT3—liver cancer	2.9e-05	6.18e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—IL6—liver cancer	2.9e-05	6.18e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—IL6—liver cancer	2.9e-05	6.18e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—TP53—liver cancer	2.89e-05	6.18e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—RAF1—liver cancer	2.89e-05	6.16e-05	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—AKT1—liver cancer	2.87e-05	6.14e-05	CbGpPWpGaD
Dipyridamole—PDE3B—GPCR downstream signaling—AKT1—liver cancer	2.87e-05	6.13e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	2.85e-05	6.09e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CASP3—liver cancer	2.85e-05	6.08e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—IL2—liver cancer	2.84e-05	6.07e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CRABP1—liver cancer	2.83e-05	6.05e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	2.83e-05	6.05e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—IL6—liver cancer	2.83e-05	6.04e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—TP53—liver cancer	2.82e-05	6.02e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—PIK3CB—liver cancer	2.82e-05	6.02e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MTOR—liver cancer	2.82e-05	6.02e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—HRAS—liver cancer	2.81e-05	5.99e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PIK3CD—liver cancer	2.78e-05	5.94e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CCND1—liver cancer	2.77e-05	5.91e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—HRAS—liver cancer	2.77e-05	5.91e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—HRAS—liver cancer	2.77e-05	5.91e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—JUN—liver cancer	2.76e-05	5.9e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	2.76e-05	5.9e-05	CbGpPWpGaD
Dipyridamole—PDE1B—GPCR downstream signaling—PIK3CA—liver cancer	2.75e-05	5.88e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—SERPINE1—liver cancer	2.75e-05	5.87e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CTNNB1—liver cancer	2.74e-05	5.86e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—PIK3CA—liver cancer	2.73e-05	5.84e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—KRAS—liver cancer	2.72e-05	5.81e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—KRAS—liver cancer	2.72e-05	5.81e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CDKN1B—liver cancer	2.72e-05	5.8e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—MYC—liver cancer	2.72e-05	5.8e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—MYC—liver cancer	2.72e-05	5.8e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—RAF1—liver cancer	2.71e-05	5.79e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—TGFB1—liver cancer	2.71e-05	5.79e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—TGFB1—liver cancer	2.71e-05	5.79e-05	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—AKT1—liver cancer	2.7e-05	5.76e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—HRAS—liver cancer	2.7e-05	5.76e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—HRAS—liver cancer	2.69e-05	5.74e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—MMP9—liver cancer	2.69e-05	5.74e-05	CbGpPWpGaD
Dipyridamole—PDE4A—GPCR downstream signaling—AKT1—liver cancer	2.69e-05	5.74e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—IL6—liver cancer	2.68e-05	5.73e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CDKN1A—liver cancer	2.68e-05	5.72e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—STAT3—liver cancer	2.67e-05	5.71e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—AKT1—liver cancer	2.67e-05	5.7e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—AKT1—liver cancer	2.67e-05	5.7e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CASP3—liver cancer	2.66e-05	5.69e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—IL2—liver cancer	2.66e-05	5.68e-05	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—PIK3CA—liver cancer	2.66e-05	5.68e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PIK3CB—liver cancer	2.65e-05	5.66e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MTOR—liver cancer	2.65e-05	5.66e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—IL6—liver cancer	2.65e-05	5.65e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—IL6—liver cancer	2.65e-05	5.65e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CDKN1B—liver cancer	2.64e-05	5.65e-05	CbGpPWpGaD
Dipyridamole—PDE3A—GPCR downstream signaling—AKT1—liver cancer	2.62e-05	5.59e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—MAPK8—liver cancer	2.62e-05	5.58e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—AKT1—liver cancer	2.61e-05	5.57e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CCND1—liver cancer	2.59e-05	5.54e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CASP3—liver cancer	2.59e-05	5.53e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—JUN—liver cancer	2.59e-05	5.53e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—IL2—liver cancer	2.59e-05	5.53e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—IL6—liver cancer	2.58e-05	5.51e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—IL6—liver cancer	2.58e-05	5.5e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CTNNB1—liver cancer	2.57e-05	5.48e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—HRAS—liver cancer	2.53e-05	5.4e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CCND1—liver cancer	2.52e-05	5.39e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—MMP9—liver cancer	2.52e-05	5.38e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—JUN—liver cancer	2.52e-05	5.38e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—KRAS—liver cancer	2.51e-05	5.36e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—KRAS—liver cancer	2.51e-05	5.36e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CDKN1A—liver cancer	2.51e-05	5.36e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—PIK3CA—liver cancer	2.5e-05	5.34e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CTNNB1—liver cancer	2.5e-05	5.33e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—PIK3CA—liver cancer	2.5e-05	5.33e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—KRAS—liver cancer	2.49e-05	5.31e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CDKN1B—liver cancer	2.49e-05	5.31e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—MYC—liver cancer	2.49e-05	5.31e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—RAF1—liver cancer	2.48e-05	5.3e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—TGFB1—liver cancer	2.48e-05	5.29e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—HPGDS—liver cancer	2.48e-05	5.29e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—AKT1—liver cancer	2.48e-05	5.29e-05	CbGpPWpGaD
Dipyridamole—PDE1A—GPCR downstream signaling—AKT1—liver cancer	2.46e-05	5.25e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MMP9—liver cancer	2.45e-05	5.23e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—MAPK8—liver cancer	2.45e-05	5.23e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—AKT1—liver cancer	2.44e-05	5.22e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—AKT1—liver cancer	2.44e-05	5.21e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CDKN1A—liver cancer	2.44e-05	5.21e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CASP3—liver cancer	2.44e-05	5.2e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—IL2—liver cancer	2.43e-05	5.2e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MTOR—liver cancer	2.42e-05	5.17e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PIK3CB—liver cancer	2.42e-05	5.17e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—IL6—liver cancer	2.42e-05	5.17e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—VEGFA—liver cancer	2.42e-05	5.16e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—STAT3—liver cancer	2.39e-05	5.11e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MAPK8—liver cancer	2.38e-05	5.09e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—AKT1—liver cancer	2.38e-05	5.08e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—AKT1—liver cancer	2.38e-05	5.07e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CCND1—liver cancer	2.37e-05	5.06e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—JUN—liver cancer	2.37e-05	5.05e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CTNNB1—liver cancer	2.35e-05	5.02e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	2.33e-05	4.98e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—HRAS—liver cancer	2.31e-05	4.94e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—HRAS—liver cancer	2.31e-05	4.93e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—PIK3CA—liver cancer	2.31e-05	4.92e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—PIK3CA—liver cancer	2.31e-05	4.92e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MMP9—liver cancer	2.3e-05	4.92e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—KRAS—liver cancer	2.3e-05	4.9e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CDKN1A—liver cancer	2.29e-05	4.9e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—PIK3CA—liver cancer	2.28e-05	4.88e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CDKN1B—liver cancer	2.27e-05	4.86e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—VEGFA—liver cancer	2.26e-05	4.83e-05	CbGpPWpGaD
Dipyridamole—PDE1B—GPCR downstream signaling—AKT1—liver cancer	2.25e-05	4.8e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MAPK8—liver cancer	2.24e-05	4.78e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—STAT3—liver cancer	2.24e-05	4.78e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—AKT1—liver cancer	2.23e-05	4.77e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CASP3—liver cancer	2.23e-05	4.76e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—IL2—liver cancer	2.23e-05	4.75e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—MYC—liver cancer	2.22e-05	4.74e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—TGFB1—liver cancer	2.22e-05	4.73e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—IL6—liver cancer	2.21e-05	4.73e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—IL6—liver cancer	2.21e-05	4.72e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PSMA4—liver cancer	2.21e-05	4.71e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PSMD10—liver cancer	2.21e-05	4.71e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—VEGFA—liver cancer	2.2e-05	4.7e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—STAT3—liver cancer	2.18e-05	4.65e-05	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—AKT1—liver cancer	2.17e-05	4.64e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CCND1—liver cancer	2.17e-05	4.63e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—JUN—liver cancer	2.17e-05	4.62e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CTNNB1—liver cancer	2.15e-05	4.59e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GOT2—liver cancer	2.15e-05	4.59e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—HRAS—liver cancer	2.13e-05	4.56e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—HRAS—liver cancer	2.13e-05	4.56e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—HRAS—liver cancer	2.11e-05	4.51e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—PIK3CA—liver cancer	2.11e-05	4.5e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MMP9—liver cancer	2.11e-05	4.5e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	2.11e-05	4.5e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CDKN1A—liver cancer	2.1e-05	4.48e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—MYC—liver cancer	2.08e-05	4.44e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—TGFB1—liver cancer	2.08e-05	4.43e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—VEGFA—liver cancer	2.07e-05	4.42e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—KRAS—liver cancer	2.05e-05	4.38e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MAPK8—liver cancer	2.05e-05	4.37e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—STAT3—liver cancer	2.05e-05	4.37e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—AKT1—liver cancer	2.04e-05	4.36e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—IL6—liver cancer	2.04e-05	4.36e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—IL6—liver cancer	2.04e-05	4.36e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—AKT1—liver cancer	2.04e-05	4.36e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MYC—liver cancer	2.02e-05	4.32e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—IL6—liver cancer	2.02e-05	4.32e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CYP2E1—liver cancer	2.02e-05	4.31e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—TGFB1—liver cancer	2.02e-05	4.31e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—HRAS—liver cancer	1.95e-05	4.17e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—PIK3CA—liver cancer	1.93e-05	4.12e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—KRAS—liver cancer	1.92e-05	4.1e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	1.9e-05	4.07e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MYC—liver cancer	1.9e-05	4.06e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—TGFB1—liver cancer	1.9e-05	4.05e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—VEGFA—liver cancer	1.89e-05	4.04e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CYCS—liver cancer	1.89e-05	4.03e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—PIK3CA—liver cancer	1.89e-05	4.03e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—AKT1—liver cancer	1.88e-05	4.02e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—AKT1—liver cancer	1.88e-05	4.02e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—STAT3—liver cancer	1.87e-05	4e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—KRAS—liver cancer	1.87e-05	3.99e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—IL6—liver cancer	1.87e-05	3.99e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—AKT1—liver cancer	1.87e-05	3.99e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GGT1—liver cancer	1.85e-05	3.96e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GOT1—liver cancer	1.85e-05	3.96e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—TP53—liver cancer	1.82e-05	3.9e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—PIK3CA—liver cancer	1.77e-05	3.77e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—KRAS—liver cancer	1.76e-05	3.75e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—HRAS—liver cancer	1.75e-05	3.73e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MYC—liver cancer	1.74e-05	3.72e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—TGFB1—liver cancer	1.74e-05	3.71e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—AKT1—liver cancer	1.72e-05	3.68e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—PIK3CA—liver cancer	1.72e-05	3.67e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—TP53—liver cancer	1.71e-05	3.65e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—IL6—liver cancer	1.67e-05	3.57e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GSTP1—liver cancer	1.67e-05	3.56e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—TP53—liver cancer	1.66e-05	3.55e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—HMOX1—liver cancer	1.64e-05	3.51e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—HRAS—liver cancer	1.63e-05	3.49e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PIK3CA—liver cancer	1.62e-05	3.45e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—KRAS—liver cancer	1.61e-05	3.43e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—HRAS—liver cancer	1.59e-05	3.39e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—AKT1—liver cancer	1.58e-05	3.37e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—IL6—liver cancer	1.56e-05	3.34e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—TP53—liver cancer	1.56e-05	3.34e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—AKT1—liver cancer	1.54e-05	3.29e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GSTM1—liver cancer	1.53e-05	3.27e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—IL6—liver cancer	1.52e-05	3.25e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—HRAS—liver cancer	1.49e-05	3.19e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PIK3CA—liver cancer	1.48e-05	3.15e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CYP1A1—liver cancer	1.45e-05	3.1e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—AKT1—liver cancer	1.44e-05	3.08e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—IL6—liver cancer	1.43e-05	3.05e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—TP53—liver cancer	1.43e-05	3.05e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—AKT1—liver cancer	1.4e-05	3e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—HRAS—liver cancer	1.37e-05	2.92e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—MTHFR—liver cancer	1.35e-05	2.89e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PPARA—liver cancer	1.33e-05	2.83e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—AKT1—liver cancer	1.32e-05	2.82e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—IL6—liver cancer	1.31e-05	2.79e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—AKT1—liver cancer	1.21e-05	2.58e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PIK3CG—liver cancer	1.14e-05	2.43e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PPARG—liver cancer	1.1e-05	2.34e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PIK3CD—liver cancer	9.99e-06	2.13e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—ALB—liver cancer	9.86e-06	2.11e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PIK3CB—liver cancer	8.71e-06	1.86e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PIK3CA—liver cancer	5.31e-06	1.13e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—AKT1—liver cancer	4.34e-06	9.26e-06	CbGpPWpGaD
